Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Front Biosci (Elite Ed). 2014;6:40-5
Authors: Jain N, O'Brien S, Thomas D, Kantarjian H
Abstract
Antibody-drug conjugates (ADCs) represent a major advance in the treatment of acute lymphoblastic leukemia (ALL). CD22 expression, seen in majority of patients with B-lineage ALL, is an ideal target for ADCs. Inotuzumab ozogamicin is an ADC comprised of a humanized IgG4 monoclonal antibody covalently linked to calecheamicin. Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. Studies exploring the combination of inotuzumab ozogamicin with chemotherapy are ongoing.
PMID: 24389139 [PubMed - indexed for MEDLINE]
Source: Frontiers in Bioscience - Elite - Category: Biomedical Science Tags: Front Biosci (Elite Ed) Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biomedical Science | Chemotherapy | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Study